Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (9): 534-537.
Previous Articles Next Articles
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo
Received:
2017-11-06
Revised:
2017-11-06
Online:
2017-09-20
Published:
2017-11-06
CLC Number:
FENG Hong-yun, FAN Yan, WU Gui-zhi, DONG Duo. Analysis and Consideration on the Reproduction Toxicity Risk of Mycophenolate Mofetil or Mycophenolic Acid[J]. Chinese Journal of Pharmacovigilance, 2017, 14(9): 534-537.
Add to citation manager EndNote|Ris|BibTeX
[1] Sollinger H W. A few memories from the beginning[J]. Transplantation, 2005, 80(Suppl 2): S178-S180. [2] Mitsui A, Suzuki S. Immunosuppressive effect of mycophenolic acid[J]. J Antibiot (Tokyo), 1969, 22(8): 358-363. [3] Carter S B, Franklin T J, Jones D F, et al. Mycophenolic acid: an anti-cancer compound with unusual properties[J]. Nature, 1969, 223(5208): 848-850. [4] Coscia L A, Armenti , King R W, et al. Update on the Teratogenicity of Maternal Mycophenolate Mofetil [J]. J Pediatr Genet, 2015, 4(2): 42-55. [5] 国家食品药品监督管理总局药品评价中心. 罗氏公司警告吗替麦考酚酯致畸风险[EB/OL]. 药物警戒快讯.(2007-12-30)[2017-08-10]. http://www.cdr-adr.org.cn/jjkx_258/ywjjkx/2007/200812/t20081216_1688.html. [6] 国家食品药品监督管理总局药品评价中心.关注麦考酚类药品的生殖毒性风险[EB/OL]. (2017-04-10)[2017-08-10]. http://www.cdr-adr.org.cn/xxtb_255/ypblfyxxtb/201704/t20170410_18365.html. [7] 黎小妍, 陶玲, 张平, 等. 吗替麦考酚酯胶囊致缺血性胸痛1例[J]. 中国医院药学杂志, 2013, 33(5): 422-423. [8] 陈鹏. 吗替麦考酚酯可致单纯红细胞再生障碍性贫血[J]. 药物不良反应杂志, 2010, 12(1): 71,73. [9] 李林芳, 毛鑫群. 肝移植术后服用吗替麦考酚酯致皮肤瘙痒1例临床护理[J].齐鲁护理杂志, 2010, 16(12): 3. [10] 闫巍, 韩修武, 邢晓燕, 等. 肾移植术后吗替麦考酚酯和硫唑嘌呤导致白细胞减少症的临床分析[J]. 河北医药, 2010, 32(7): 784-786. [11] 朱兰, 刘可欣, 唐尧.吗替麦考酚酯服用患者全身性感染猪霍乱菌血症1例[J]. 现代预防医学, 2008, 35(9): 1797. [12] 张芳, 陈安进, 余顺香. 麦考酚吗乙酯致持续高热[J]. 药物不良反应杂志, 2007, 9(6): 441,447. [13] 蒋燕, 梁蓉梅, 王晓蕙. 吗替麦考酚酯致耳鸣1例[J]. 药学实践杂志, 2001, 19(6): 359. [14] 李军, 陈昊, 杨守国, 等. 心脏移植后吗替麦考酚酯的个体化应用[J]. 中华器官移植杂志, 2013, 34(3): 139-143. [15] 孙建, 李雯. 吗替麦考酚酯治疗系统性红斑狼疮并重度血小板减少11例疗效观察[J]. 中华实用诊断与治疗杂志, 2011, 25(5): 491-492. [16] 吴东海, 孙凌云, 杨南萍, 等. 吗替麦考酚酯联合糖皮质激素治疗狼疮性肾炎的疗效及安全性: 开放性多中心研究[J]. 中华临床免疫和变态反应杂志, 2008, 2(3): 190-193. [17] 陈香美, 陈仆, 蔡广研, 等. 麦考酚酸酯治疗IgA肾病的随访对照观察[J]. 中华医学杂志, 2002, 82(12): 796-801. [18] 刘春雅. 吗替麦考酚酯治疗原发性膜性肾病的临床疗效[J]. 中华全科医学, 2014, 12(2): 220-222. [19] 赵德安, 毕凌云, 杨达胜, 等. 吗替麦考酚酯治疗以蛋白尿为主的儿童紫癜性肾炎疗效观察[J]. 临床儿科杂志, 2011, 29(4): 328-330. [20] 张光峰, 徐婷, 张红卫, 等. 吗替麦考酚酯与环磷酰胺治疗结缔组织病相关肺间质病变的随机对照研究[J]. 中华医学杂志, 2015, 95(45): 3641-3645. [21] 向雅娟, 何洋, 杨亭亭, 等. 吗替麦考酚酯联合皮质类固醇激素治疗多发性硬化和视神经脊髓炎疗效的初步观察[A]. 2015北京医学会神经病学学术年会论文集, 2015:157-157. [22] 郭生红, 李薇, 夏登梅. 单用泼尼松及联用吗替麦考酚酯、硫唑嘌呤治疗天疱疮近期临床观察[J]. 临床皮肤科杂志, 2014, 43(3): 143-147. [23] 国家食品药品监督管理总局药品评价中心. 使用重组人红细胞生成素应控制血红蛋白浓度、警惕吗替麦考酚酯的生殖毒性、警惕抗抑郁药治疗过程中的自杀风险[EB/OL]. (2008-12-16)[2017-08-10]. http://www.cdr-adr.org.cn/xxtb_255/ypblfyxxtb/200812/t20081216_2818.html. [24] FDA. Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic[EB/OL]. (2009-05-06)[2017-08-10]. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/ucm148735.htm. [25] EMA. EMA recommends additional measures to prevent use of mycophenolate in pregnancy[EB/OL].(2015-10-23)[2017-08-10]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002418.jsp&mid=WC0b01-ac058004d5c1. [26] MHRA. Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men[EB/OL]. (2015-12-14)[2017-08-10]. https://www.gov.uk/drug-safety-update/mycophenolate-mofetil-mycophenolic-acid-new-pregnancy-prevention-advice-for-women-and-men. [27] CFDA.总局关于修订麦考酚类药品说明书的公告(2017年第35号)[EB/OL]. (2017-03-28)[2017-08-10]. http://www.sda.gov.cn/WS01/CL1706/171211.html. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||